BLA 761119 · Lundbeck Seattle Biopharmaceuticals, Inc.
Vyepti
Eptinezumab-Jjmr · Injection · Calcitonin Gene-related Peptide Antagonist
NovelLast checked: Nov 20, 2026Latest source record: Jun 5, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Feb 21, 2020
Approved uses
3
Original approval plus efficacy supplements
Registered trials
30
16 Phase 3, 9 recruiting
FAERS reports
9,754
2,514 serious, 68 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 5, 2026.
VYEPTI is indicated for the preventive treatment of migraine in adults. VYEPTI is a calcitonin gene-related peptide antagonist indicated for the preventive treatment of migraine in adults ( 1 )
Mechanism: Eptinezumab-jjmr is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 22, 2025 Supplement 11 · Efficacy LetterLabel
- Aug 18, 2025 Supplement 10 · Efficacy
- Feb 21, 2020 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
- VYEPTI · EPTINEZUMAB-JJMR 100MG/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Eptinezumab" as an intervention, any sponsor and status, largest first.
- Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic MigrainePivotal-lookingCompleted
Alder Biopharmaceuticals, Inc.Industry
NCT02974153 · 1,121 participants · Start Nov 2016 · Primary completion Nov 2017
Drug: ALD403 (Eptinezumab); Placebo · For: Migraine Disorders
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 144 sites in all
- Eptinezumab as Preventive Treatment of Migraine in Adults With MigrainePivotal-lookingCompleted
H. Lundbeck A/SIndustry
NCT04921384 · 981 participants · Start May 29, 2021 · Primary completion Oct 1, 2024
Drug: Placebo; Eptinezumab · For: Migraine
Sites: Beijing, China; Guangzhou, China; Zhengzhou, China · 87 sites in all
- A Multicenter Assessment of ALD403 in Frequent Episodic MigrainePivotal-lookingCompleted
Alder Biopharmaceuticals, Inc.Industry
NCT02559895 · 898 participants · Start Sep 2015 · Primary completion Feb 2017
Drug: ALD403; Placebo · For: Migraine Disorders
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 87 sites in all
- A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive TreatmentsPivotal-lookingCompleted
H. Lundbeck A/SIndustry
NCT04418765 · 892 participants · Start Jun 1, 2020 · Primary completion Jul 15, 2021
Drug: Eptinezumab; Placebo · For: Migraine
Sites: Walnut Creek, California; Gainesville, Florida; Maitland, Florida · 138 sites in all
- A Multicenter Assessment of ALD403 in Chronic MigrainePivotal-lookingCompleted
Alder Biopharmaceuticals, Inc.Industry
NCT02275117 · 665 participants · Start Oct 2014 · Primary completion Mar 2016
Drug: ALD403; Placebo · For: Migraine Disorders
Sites: Huntsville, Alabama; Mobile, Alabama; Phoenix, Arizona · 92 sites in all
- A Study of Eptinezumab in Participants With Migraine and Medication Overuse HeadachePivotal-lookingCompleted
H. Lundbeck A/SIndustry
NCT05452239 · 608 participants · Start Jul 1, 2022 · Primary completion Oct 22, 2024
Drug: Eptinezumab; Placebo · For: Migraine; Medication Overuse Headache
Sites: Winter Haven, Florida; Marrero, Louisiana; Springfield, Missouri · 76 sites in all
- A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic MigrainePivotal-lookingRecruiting
H. Lundbeck A/SIndustry
NCT05164172 · 600 participants (planned) · Start Dec 1, 2021 · Primary completion Apr 30, 2028
Drug: Eptinezumab · For: Migraine
Sites: New Haven, Connecticut; Stamford, Connecticut; Gainesville, Florida · 64 sites in all
- A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of MigrainePivotal-lookingCompleted
H. Lundbeck A/SIndustry
NCT04152083 · 485 participants · Start Nov 7, 2019 · Primary completion Jul 8, 2020
Drug: Eptinezumab; Placebo · For: Migraine
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 57 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective2,135
- migraine1,565
- headache1,024
- therapeutic response shortened602
- nausea575
- fatigue526
- throat irritation384
- drug effect less than expected383
- dizziness382
- pruritus343
- nasal congestion275
- dyspnoea229
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 2 |
| 2019 | 2 |
| 2020 | 156 |
| 2021 | 750 |
| 2022 | 1,262 |
| 2023 | 1,668 |
| 2024 | 2,246 |
| 2025 | 2,064 |
| 2026 | 1,604 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vyepti (Eptinezumab-Jjmr)
2024 spending
$15.1M
Beneficiaries
1,502
3,789 claims
Per beneficiary
$10,020
$1,657.25 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $480,832 |
| 2021 | $2,345,427 |
| 2022 | $4,668,437 |
| 2023 | $8,873,945 |
| 2024 | $15,050,143 |
Part B: Vyepti (Eptinezumab-Jjmr) · HCPCS J3032
2024 spending
$70.6M
Beneficiaries
6,392
17,819 claims
Per beneficiary
$11,049
2024 ASP limit $18.36 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,155,143 |
| 2021 | $12,936,886 |
| 2022 | $25,996,801 |
| 2023 | $45,074,964 |
| 2024 | $70,625,022 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1).
Ashina M, Saper J, Cady R, et al. · Cephalalgia 2020 · Clinical Trial, Phase III, Controlled Clinical Trial
- Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials.
Haghdoost F, Puledda F, Garcia-Azorin D, et al. · Cephalalgia 2023 · Systematic Review, Network Meta-Analysis
- 2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies.
Robblee J, Minen MT, Friedman BW, et al. · Headache 2026 · Systematic Review, Meta-Analysis
- Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2.
Lipton RB, Goadsby PJ, Smith J, et al. · Neurology 2020 · Clinical Trial, Phase III, Multicenter Study
- Efficacy and safety of eptinezumab in patients with chronic migraine and medication-overuse headache: a randomized, double-blind, placebo-controlled study.
Yu S, Zhou J, Luo G, et al. · BMC Neurol 2023 · Clinical Trial, Phase III, Multicenter Study
- Effectiveness and Tolerability of Pharmacologic Prophylaxis for Chronic Migraine : A Systematic Review of Randomized Controlled Trials.
Khalili M, Haghdoost F, Liaghatdar A, et al. · Ann Intern Med 2026 · Systematic Review, Meta-Analysis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.